Question 1

What is Supernus Pharmaceuticals, Inc.'s WACC?

Accepted Answer

Supernus Pharmaceuticals, Inc. (SUPN) has a Weighted Average Cost of Capital (WACC) of 7.81%. This is calculated using a Cost of Equity of 7.81% (via CAPM with a beta of 0.61) and a pre-tax Cost of Debt of 5.00%, with an equity weight of 100.00% in the capital structure.

Question 2

Is Supernus Pharmaceuticals, Inc.'s WACC high or low?

Accepted Answer

Supernus Pharmaceuticals, Inc.'s WACC of 7.81% is below the typical range of 8-12% for most companies, indicating relatively low cost of capital and lower risk. WACC is used as the discount rate in DCF valuations — a lower WACC results in higher present values of future cash flows.

Question 3

How is Supernus Pharmaceuticals, Inc.'s WACC calculated?

Accepted Answer

Supernus Pharmaceuticals, Inc.'s WACC is calculated using the formula: WACC = (E/V × Re) + (D/V × Rd × (1-T)). The Cost of Equity (Re) of 7.81% is derived from the CAPM model using a beta of 0.61. The pre-tax Cost of Debt (Rd) is 5.00%. The capital structure is 100.00% equity and 0.00% debt.

Supernus Pharmaceuticals, Inc. (SUPN) — WACC 分析

WACC 构成

解读

Supernus Pharmaceuticals, Inc.（SUPN）WACC：7.81%

WACC计算器

Supernus Pharmaceuticals, Inc.（SUPN） WACC 解读

SUPN 公司分析

SUPN DCF 估值

继续做同行对比